Carbidopa
Sinemet is the only carbidopa product on this shelf, pairing it with levodopa across three strength combinations to treat Parkinson’s Disease and Parkinsonism in the Neurology category.
Key points
- Carbidopa is a decarboxylase inhibitor: it prevents much of levodopa from breaking down before it reaches the brain.
- This allows levodopa to address dopamine-related movement symptoms with less peripheral nausea and vomiting.
- Stopping carbidopa-levodopa suddenly can cause a serious syndrome with fever, rigidity, unusual movements and confusion.
What the strengths mean on the label
Sinemet pairs levodopa with carbidopa in three fixed combinations: 100 mg + 10 mg, 100 mg + 25 mg, and 250 mg + 25 mg. Carbidopa appears only inside combination tablets in this listing; there is no single-ingredient product. Stalevo adds entacapone to the same levodopa-carbidopa base, giving a third ingredient on top of the two already present in Sinemet.